Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Multiple Myeloma 9Recurrence 2Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic 1Leukemia, Plasma Cell 1Immunoglobulin Light-chain Amyloidosis 1Hematologic Neoplasms 1Amyloidosis 1

Interventions

Docetaxel 11Prednisone 10Leuprolide 10Magnetic Resonance Spectroscopy 9bicalutamide 8Radiotherapy 7Abiraterone Acetate 7Biopsy 6gallium 68 PSMA-11 5acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 5Surveys and Questionnaires 5Metformin 5Goserelin 5radium Ra 223 dichloride 4enzalutamide 4apalutamide 4Specimen Handling 4Injections 4Androgen Antagonists 4pembrolizumab 3orteronel 3cabazitaxel 3abiraterone 3Radiotherapy, Intensity-Modulated 3Radiosurgery 3Pioglitazone 3Paclitaxel 3Exercise 3Brachytherapy 3Blood Specimen Collection 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Prostatic Neoplasms × daratumumab × Clear all
NCT03035357 2024-05-03

Neoadjuvant Listeria or Daratumumab in Prostate Cancer

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡